Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma
- Status
- SUSPENDED
- Phase
- PHASE2
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
- Status
- RECRUITING
- Phase
- N/A
EPO906 Therapy in Patients With Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
ADI-PEG in Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Novel Adjuvants for Peptide-Based Melanoma Vaccines
- Status
- COMPLETED
- Phase
- PHASE1
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
- Status
- COMPLETED
- Phase
- N/A
Vaccine Therapy in Treating Patients With Metastatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Thalidomide and Dacarbazine for Metastatic Melanoma
- Status
- UNKNOWN
- Phase
- PHASE2
Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
- Status
- COMPLETED
- Phase
- PHASE3
Microarray Analysis for Human Genetic Disease
- Status
- COMPLETED
- Phase
- N/A
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Evaluation for NCI Surgery Branch Clinical Research Protocols
- Status
- RECRUITING
- Phase
- N/A
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
- Status
- COMPLETED
- Phase
- PHASE2
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
- Status
- COMPLETED
- Phase
- PHASE1
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
- Status
- COMPLETED
- Phase
- N/A